H
Hideki Origasa
Researcher at University of Toyama
Publications - 259
Citations - 10976
Hideki Origasa is an academic researcher from University of Toyama. The author has contributed to research in topics: Stroke & Atrial fibrillation. The author has an hindex of 47, co-authored 245 publications receiving 9390 citations. Previous affiliations of Hideki Origasa include Mochida Pharmaceutical Co., Ltd.
Papers
More filters
Journal ArticleDOI
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
Mitsuhiro Yokoyama,Hideki Origasa,Masunori Matsuzaki,Yuji Matsuzawa,Yasushi Saito,Yuichi Ishikawa,Shinichi Oikawa,Jun Sasaki,Hitoshi Hishida,Hiroshige Itakura,Toru Kita,Akira Kitabatake,Noriaki Nakaya,Toshiie Sakata,Kazuyuki Shimada,Kunio Shirato +15 more
TL;DR: Testing the hypothesis that long-term use of eicosapentaenoic acid (EPA) is effective for prevention of major coronary events in hypercholesterolaemic patients in Japan who consume a large amount of fish found it to be a promising treatment.
Journal ArticleDOI
Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination.
Hiroshi Inoue,Akira Fujiki,Hideki Origasa,Satoshi Ogawa,Ken Okumura,Isao Kubota,Yoshifusa Aizawa,Takeshi Yamashita,Hirotsugu Atarashi,Minoru Horie,Tohru Ohe,Yoshinori Doi,Akihiko Shimizu,Akiko Chishaki,Tetsunori Saikawa,Katsusuke Yano,Akira Kitabatake,Hideo Mitamura,Itsuo Kodama,Shiro Kamakura +19 more
TL;DR: The prevalence of AF increased in Japan as the population aged, as in Western countries, and the overall prevalence in Japan is approximately two-thirds of that in the USA.
Journal ArticleDOI
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Yasushi Saito,Mitsuhiro Yokoyama,Hideki Origasa,Masunori Matsuzaki,Yuji Matsuzawa,Yuichi Ishikawa,Shinichi Oikawa,Jun Sasaki,Hitoshi Hishida,Hiroshige Itakura,Toru Kita,Akira Kitabatake,Noriaki Nakaya,Toshiie Sakata,Kazuyuki Shimada,Kunio Shirato +15 more
TL;DR: EPA was effective in reducing the incidence of CAD events for patients with this dyslipidemic pattern, suggesting that EPA may be especially beneficial in patients who with abnormal TG and HDL-C levels.
Journal ArticleDOI
Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)
TL;DR: The Japanese Diastolic Heart Failure Study (J‐DHF) is a multicentre, prospective, randomized, open, blinded‐endpoint trial, designed to assess the effects of carvedilol in HFPEF patients.
Journal ArticleDOI
Low-Dose Aspirin for Prevention of Stroke in Low-Risk Patients With Atrial Fibrillation: Japan Atrial Fibrillation Stroke Trial
Hiroshi Sato,Kinji Ishikawa,Akira Kitabatake,Satoshi Ogawa,Yukio Maruyama,Yoshiyuki Yokota,Takaya Fukuyama,Yoshinori Doi,Seibu Mochizuki,Tohru Izumi,Noboru Takekoshi,Kiyoshi Yoshida,Katsuhiko Hiramori,Hideki Origasa,Shinichiro Uchiyama,Masayasu Matsumoto,Takenori Yamaguchi,Masatsugu Hori +17 more
TL;DR: For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe, and further prospective studies are needed to determine the best preventive therapy for cerebrovascular events in Japanese patients withNVAF.